These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25485725)

  • 1. Diagnosis of Graves' orbitopathy (DiaGO): results of a pilot study to assess the utility of an office tool for practicing endocrinologists.
    Mitchell AL; Goss L; Mathiopoulou L; Morris M; Vaidya B; Dickinson AJ; Quinn A; Dayan C; McLaren J; Hickey JL; Lazarus JH; Rose GE; Foley P; MacEwen CJ; Perros P
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E458-62. PubMed ID: 25485725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raising awareness of Graves' orbitopathy with early warning cards.
    Mitchell AL; Hickey J; Vaidya B; Mason R; Ajjan R; Zammitt N; Perros P; Dayan C;
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):853-859. PubMed ID: 28755510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
    Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.
    Perros P; Žarković M; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi A; Bournaud C; Brix TH; Covelli D; Ćirić S; Daumerie C; Eckstein A; Fichter N; Führer D; Hegedüs L; Kahaly GJ; Konuk O; Lareida J; Lazarus J; Leo M; Mathiopoulou L; Menconi F; Morris D; Okosieme O; Orgiazzi J; Pitz S; Salvi M; Vardanian-Vartin C; Wiersinga W; Bernard M; Clarke L; Currò N; Dayan C; Dickinson J; Knežević M; Lane C; Marcocci C; Marinò M; Möller L; Nardi M; Neoh C; Pearce S; von Arx G; Törüner FB
    Br J Ophthalmol; 2015 Nov; 99(11):1531-5. PubMed ID: 25953846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Management of Graves' orbitopathy: evidence-based recommendations].
    Ponto KA; Pitz S; Mann WJ; Weber MM; Pfeiffer N; Kahaly GJ
    Dtsch Med Wochenschr; 2009 Dec; 134(49):2521-4. PubMed ID: 19941237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Death by Suicide in Graves' Disease and Graves' Orbitopathy: A Nationwide Danish Register Study.
    Ferløv-Schwensen C; Brix TH; Hegedüs L
    Thyroid; 2017 Dec; 27(12):1475-1480. PubMed ID: 29084476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating Graves' orbitopathy.
    Dolman PJ
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):229-48. PubMed ID: 22632361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased TRAb and/or low anti-TPO titers at diagnosis of graves' disease are associated with an increased risk of developing ophthalmopathy after onset.
    Lantz M; Planck T; Asman P; Hallengren B
    Exp Clin Endocrinol Diabetes; 2014 Feb; 122(2):113-7. PubMed ID: 24554511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity.
    Slowik M; Urbaniak-Kujda D; Bohdanowicz-Pawlak A; Kapelko-Slowik K; Dybko J; Wolowiec D; Jazwiec B; Daroszewski J
    Endocr Res; 2012; 37(2):89-95. PubMed ID: 22489922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Graves' orbitopathy in Latin America: an international questionnaire study compared with Europe.
    Ramos HE; Diehl LA; Camacho CP; Perros P; Graf H;
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):951-6. PubMed ID: 18462263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative proteomic analysis of tear fluid in Graves' disease with and without orbitopathy.
    Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
    Clin Endocrinol (Oxf); 2016 Nov; 85(5):805-812. PubMed ID: 27256639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral conjunctivitis interfering with the clinical activity score and management of thyroid ophthalmopathy.
    Boboridis KG; Konstas AG; Krassas GE; Georgiadis NS
    Orbit; 2006 Mar; 25(1):27-9. PubMed ID: 16527772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathways.
    Perros P; Dayan CM; Dickinson AJ; Ezra D; Estcourt S; Foley P; Hickey J; Lazarus JH; MacEwen CJ; McLaren J; Rose GE; Uddin J; Vaidya B
    Clin Med (Lond); 2015 Apr; 15(2):173-8. PubMed ID: 25824071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study.
    Sabini E; Mazzi B; Profilo MA; Mautone T; Casini G; Rocchi R; Ionni I; Menconi F; Leo M; Nardi M; Vitti P; Marcocci C; Marinò M
    Thyroid; 2018 Mar; 28(3):386-394. PubMed ID: 29336220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal management of Graves orbitopathy: a multidisciplinary approach.
    Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
    Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality in Graves' orbitopathy is increased and influenced by gender, age and pre-existing morbidity: a nationwide Danish register study.
    Schwensen CF; Brandt F; Hegedüs L; Brix TH
    Eur J Endocrinol; 2017 Jun; 176(6):669-676. PubMed ID: 28258132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine therapy and Graves' ophthalmopathy.
    Sisson JC; Schipper MJ; Nelson CC; Freitas JE; Frueh BR
    J Nucl Med; 2008 Jun; 49(6):923-30. PubMed ID: 18483104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study.
    Lanzolla G; Sabini E; Profilo MA; Mazzi B; Sframeli A; Rocchi R; Menconi F; Leo M; Nardi M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2018 Dec; 41(12):1417-1423. PubMed ID: 29923059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.
    Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
    PLoS One; 2017; 12(4):e0175274. PubMed ID: 28419103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between interleukin 21 and Graves' disease.
    Jia HY; Zhang ZG; Gu XJ; Guo T; Cui B; Ning G; Zhao YJ
    Genet Mol Res; 2011 Oct; 10(4):3338-46. PubMed ID: 22057994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.